Efficacy of intradermal vaccination

Hunsaker, Breck D.; Perino, Louis J.

doi:10.1016/s0165-2427(01)00244-6

Cited by 24 publications

(18 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in the in vivo experiment, intradermal immunization with these responding histone peptides, except H3 111-130 , did not affect disease pathogenesis. These peptides include H4 [21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40] and H4 71-90 , which most sequences overlapped with H4 and H4 71-94 , respectively, as mentioned above (7). However, it was surprising to observe that administration of the H3 111-130 peptide, which most sequences overlapped with H3 118-132 , as previously described (7), can significantly delay the onset of severe nephritis in BWF 1 mice.…”

Section: Discussionmentioning

confidence: 99%

“…splenic CD4ϩ T cells from all disease-developing BWF 1 mice. T cells from some, but not all, BWF 1 mice were able to respond to H2B [31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50] (Figure 3B) or H3 111-130 ( Figure 3C). In addition, these CD4ϩ T cells were stimulated by several overlapping peptides from H4 ( Figure 3D), such as in regions 21-40, 61-80, 71-90, 81-100, and 91-103.…”

Section: Development In Bwf 1 Mice Of a Spontaneous Cd4؉ T Cell Prolimentioning

confidence: 99%

“…To further investigate the role of responding histone peptides in vivo, 14-week-old prenephritic BWF 1 mice were intradermally immunized with OVA 323-339 , H2A 101-120 , H2B [31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50] , H3 111-130 , H4 [21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40] , H4 71-90 , or H4 81-100 peptide (100 g/mouse) emulsified in adjuvant, and the control group of mice received PBS mixed with adjuvant. Each group of mice received 3 additional injections at 2-week or 3-week intervals, as indicated in Figure 4A.…”

Section: Suppression Of Lupus Development In Mice By Intradermal Immumentioning

confidence: 99%

See 2 more Smart Citations

Treatment of murine lupus using nucleosomal T cell epitopes identified by bone marrow–derived dendritic cells

Suen¹,

Chuang²,

Tsai³

et al. 2004

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. Systemic lupus erythematosus (SLE) is characterized by the existence of a heterogeneous group of autoantibodies directed against intact nuclear structures, such as nucleosomes. The most prominent of these autoantibodies are those directed against doublestranded DNA (dsDNA) and histones. The majority are of the IgG isotype and show affinity maturation, both of which are known hallmarks of T cell help. Much evidence suggests that the nucleosome is a major candidate autoantigen in SLE. In this study, a novel strategy was used to identify the critical CD4؉ T cell autoepitopes in nucleosomes. In addition, peptide-based therapy was then performed in a lupus animal model.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Development In Bwf 1 Mice Of a Spontaneous Cd4؉ T Cell Prolimentioning

confidence: 99%

Section: Suppression Of Lupus Development In Mice By Intradermal Immumentioning

confidence: 99%

See 1 more Smart Citation

Treatment of murine lupus using nucleosomal T cell epitopes identified by bone marrow–derived dendritic cells

Suen¹,

Chuang²,

Tsai³

et al. 2004

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…Studies show that intradermal vaccination offers better protection than the other routes of immunization (9). The delivery of vaccines to the epidermal layer of the skin is a major challenge while using needle injections.…”

mentioning

confidence: 99%

Needleless Vaccine Delivery Using Micro-Shock Waves

Jagadeesh

Prakash

Rakesh

et al. 2011

Clin Vaccine Immunol

View full text Add to dashboard Cite

Shock waves are one of the most efficient mechanisms of energy dissipation observed in nature. In this study, utilizing the instantaneous mechanical impulse generated behind a micro-shock wave during a controlled explosion, a novel nonintrusive needleless vaccine delivery system has been developed. It is well-known that antigens in the epidermis are efficiently presented by resident Langerhans cells, eliciting the requisite immune response, making them a good target for vaccine delivery. Unfortunately, needle-free devices for epidermal delivery have inherent problems from the perspective of the safety and comfort of the patient. The penetration depth of less than 100 m in the skin can elicit higher immune response without any pain. Here we show the efficient utilization of our needleless device (that uses micro-shock waves) for vaccination. The production of liquid jet was confirmed by high-speed microscopy, and the penetration in acrylamide gel and mouse skin was observed by confocal microscopy. Salmonella enterica serovar Typhimurium vaccine strain pmrG-HM-D (DV-STM-07) was delivered using our device in the murine salmonellosis model, and the effectiveness of the delivery system for vaccination was compared with other routes of vaccination. Vaccination using our device elicits better protection and an IgG response even at a lower vaccine dose (10-fold less) compared to other routes of vaccination. We anticipate that our novel method can be utilized for effective, cheap, and safe vaccination in the near future.Shock waves appear in nature whenever the different elements in a fluid approach one another with a velocity faster than the local speed of sound (8). Shock waves are essentially nonlinear waves that propagate at supersonic speeds. Such disturbances occur in steady transonic or supersonic flows during explosions, earthquakes, tsunamis, lightning strikes, and contact surfaces in laboratory devices. Any sudden release of energy (within a few microseconds) will invariably result in the formation of a shock wave, since it is one of the efficient mechanisms of energy dissipation observed in nature. The dissipation of mechanical, nuclear, chemical, and electrical energy in a limited space will result in the formation of a shock wave. However, it is possible to generate micro-shock waves in the laboratory by different methods, including controlled explosions. One of the unique features of shock wave propagation in any medium (solid, liquid, or gases) is their ability to instantaneously increase the pressure and temperature of the medium. Researchers are exploiting this behavior of shock waves to develop novel

show abstract

“…The increased immunogenicity of antigens delivered via the i.d. route may reflect the high density of immune stimulatory cells, such as Langerhans cells and dermal dendritic cells, which are usually resident in the skin (23). In addition, the i.d.…”

mentioning

confidence: 99%

Distinctive Immunomodulatory and Inflammatory Properties of the Escherichia coli Type II Heat-Labile Enterotoxin LT-IIa and Its B Pentamer following Intradermal Administration

Mathias-Santos¹,

Rodrigues²,

Sbrogio-Almeida³

et al. 2011

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

Cholera toxin (CT) and heat-labile enterotoxins (LTs) produced by Vibrio cholerae and by some enterotoxigenic Escherichia coli (ETEC) strains, respectively, belong to the family of AB (A 1 B 5 )-type bacterial enterotoxins. The A 1 B 5 enterotoxins have an enzymatically active A subunit (28 kDa) that is noncovalently associated to a pentamer composed of five B polypeptides (11.5 kDa each). While the A polypeptide confers the catalytic activity, the B pentamer is responsible for binding to gangliosides and/or galactose-containing surface receptors found on the surface of eukaryotic cells (39). In addition to their roles as virulence determinants directly involved with the watery diarrhea caused by these bacterial pathogens, both CT and LT have received considerable interest due to their remarkable immunomodulatory effects in different mammalian species when they are delivered via parenteral, mucosal, or transcutaneous routes (3,15,21,28,31,38,43).Based on genetic, biochemical, and immunological features, two major groups of heat-labile enterotoxins have been described (17, 20). Type I enterotoxins produced by ETEC strains share high similarity with V. cholerae CT and include the reference LT produced by the H10407 strain (here termed LT-I) while type II enterotoxins (LT-IIa, LT-IIb, and LT-IIc) are usually isolated from ETEC strains derived from nonhuman hosts (16,33,37). Although the A peptides of type I and type II enterotoxins are highly homologous, the two toxin groups differ largely in the B subunit amino acid sequences (Ͻ14% sequence identity). The different B subunit sequences reflect, at least in part, differential receptor specificity and some distinct immunological features of type I and type II enterotoxins (1,5,20). Indeed, previous studies showed that LT-I binds with high affinity to the GM1 ganglioside and, with lower affinity, to a few other galactose-containing surface components such as GM2, asialo-GM1, GD2, GD1b, and paraglobosides while LT-IIa binds most avidly to the GD1b ganglioside and less strongly to other ganglioside receptors (GT1b, GD2, GD1a, GM1, and GM2) (13,40). Interestingly, the B pentamer of LT-IIa (LT-IIaB 5 ), but not the holotoxin, interacts with Toll-like receptor 2 (TLR2) to induce secretion of proinflammatory cytokines (19).Several reports demonstrated that the adjuvant and immunomodulatory properties of LT-IIa correlate with the presence of a functional B subunit (1,32,34). Coadministration of LT-IIa and purified antigens via the nasal route promotes enhanced antigen-specific mucosal (IgA) and systemic (IgG) antibody responses and in vitro activation of T lymphocytes (31). In contrast, a receptor-binding-deficient mutant of LT-IIa lost most of the immunomodulatory properties (34). Nonetheless, while a plethora of studies have characterized the adjuvant properties of LT-I when it is delivered via parenteral

show abstract

Efficacy of intradermal vaccination

Cited by 24 publications

References 37 publications

Treatment of murine lupus using nucleosomal T cell epitopes identified by bone marrow–derived dendritic cells

Treatment of murine lupus using nucleosomal T cell epitopes identified by bone marrow–derived dendritic cells

Needleless Vaccine Delivery Using Micro-Shock Waves

Distinctive Immunomodulatory and Inflammatory Properties of the Escherichia coli Type II Heat-Labile Enterotoxin LT-IIa and Its B Pentamer following Intradermal Administration

Contact Info

Product

Resources

About